Here's Why Nevro Is Skyrocketing Today
After Nevro Corp. (NYSE: NVRO), a medical device company focused on pain management, shared a number of corporate updates with investors, its shares rose 35% as of 10:55 a.m. EDT on Wednesday.
Nevro announced the following corporate changes today:
- D. Keith Grossman has been hired as the company's new President and CEO, effective immediately. He has previously held executive roles at other medical device companies called Thoratec Corporation and Conceptus, both of which were ultimately acquired. He succeeds former CEO Rami Elghandour, who was hired in 2012 and no longer has any role at the company.
- Two new independent directors have been appointed: Elizabeth Weatherman, who is a limited partner at the private equity firm Warburg Pincus, and Kevin O'Boyle, a medical device executive with 20 years of experience.
- Ali Behbahani has resigned as a member of the Board.
- Nervo is suspending its revenue guidance for the year in light of the management change.
A lot of these changes were made under the guidance of Broadfin Capital, which is a global equity healthcare manager that holds a significant amount of Nevro stock.
Here's the commentary that Michael DeMane, Nervo's Chairman of the Board, shared with investors regarding the management change:
Keith Grossman appears to have a successful track record of value creation behind him, so it's understandable why traders are cheering today.
Nervo has come up short of analyst estimates on its last four earnings reports, so it's understandable why the Board felt that change was necessary.
Will the new CEO be able to turbocharge the company's growth rate and create shareholder value? Only time will tell. Since leadership changes can be difficult on employees and customers, I think that caution is warranted.
10 stocks we like better than NevroWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Nevro wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of March 1, 2019
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.